Recently, Wanbang Biopharma, the subsidiary of Fosun Pharma has entered into an agreement in Shanghai with a German company, Biotest. According to the Agreement, Wanbang Biopharma will be the exclusive agent to sell Biotest’s human serum albumin (HSA) product, Albiomin^® in mainland China. IMS statistics show that HAS hospital sales in 2011 is close to 3.5 billion yuan.
As a special drug widely used in intensive care, HSA is the albumin extracted from the plasma of healthy human, with main indications of hemorrhagic trauma, burn-caused shock, brain edema and intracranial pressure increase caused by injury, hepatic cirrhosis and hydropsia or ascites caused by nephropathy. In China, the demand for HSA is increasing in recent years while supply shortage takes place from time to time. Founded in 1946, Biotest is a world leading company in R&D and manufacturing of plasma-derived and biological products, being listed in Frankfurt Stock Exchange in 1987, and selected in Deutsche Börse SDAX index in 2007. Biotest’s capability of separating and purifying high value medicinal ingredients from plasma is prominent among its global counterparts. It follows strict standard during plasma collection, testing and production to ensure stable and reliable product quality. The cooperation between Biotest and Fosun Pharma will help ease the supply shortage of HSA in China market and create good social benefits.
Fosun Pharma has rich marketing resources and high capability in China, and long-term commitment to the international development strategy. After its shares being listed on SEHK in October 2012, Fosun Pharma is more actively devoting itself to international development while focusing on its core businesses. Fosun Pharma further enforces its core businesses and expands comprehensive cooperation model with outstanding overseas pharmaceutical companies through the cooperation with Biotest.